Microcap Ledger HCW Biologics Inc. $HCWB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Miramar, FL
- Fiscal year end
- December 31
- Shares outstanding
- 1,836,324 [10-Q/A 2026-08-14]
What the company doesAI summary of filing
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions. The company generates revenue from out-licensing agreements, including a deal with Wugen for cell-based cancer therapies and a recent agreement with Trimmune for development rights in China, and has commercialized two proprietary fusion proteins (HCW9206 and HCW9201) as reagents for manufacturing CAR-T and NK cell therapies. Its lead clinical-stage candidate, HCW9302, began a first-in-human Phase 1 trial in November 2025 for alopecia areata, with additional preclinical programs targeting solid tumors and bronchopulmonary dysplasia expected to enter clinical trials in 2027. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $6.65M | −$1.75M | −$5.54M | $741.3K | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $54.2K | −$7.96M | −$13.39M | $1.95M | [10-K 2026-03-31] |
| FY ended Dec 2024 | $2.57M | −$30.02M | −$14.23M | $4.67M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$2.77M
- Cash runway Estimate
- ~0.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-25 | 44,934,120 | [10-K 2025-03-28] |
| 2025-05-13 | 1,439,219 | [10-Q 2025-05-15] |
| 2025-08-12 | 2,151,607 | [10-Q 2025-08-18] |
| 2025-11-11 | 2,701,607 | [10-Q 2025-11-14] |
| 2026-03-25 | 6,734,104 | [10-K 2026-03-31] |
| 2026-05-14 | 6,734,104 | [10-Q 2026-05-14] |
| 2026-08-12 | 1,836,324 | [10-Q 2026-08-14] |
| 2026-08-14 | 1,836,324 | [10-Q/A 2026-08-14] |
- Shelf registration
- S-1 filed 2026-10-02; no effectiveness notice found in EDGAR [S-1 2026-10-02]
Listing status
Current status: 8 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-06-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-06-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-30] |
| 2026-06-01 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-01] |
| 2026-03-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-02] |
| 2025-10-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-16] |
| 2025-08-19 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-19] |
| 2025-03-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-06] |
| 2025-02-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-07] |
| 2024-12-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-23] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-29 | Wong Hing C | buy | 23,210 | $2.58 | [4 2026-07-31] |
| 2026-07-29 | Flowers Lee | buy | 7,736 | $2.58 | [4 2026-07-31] |
| 2026-07-29 | Garrett Scott T | buy | 7,736 | $2.58 | [4 2026-07-31] |
| 2026-05-22 | Wong Hing C | buy | 113,879 | $1.41 | [4 2026-05-27] |
| 2026-05-22 | Garrett Scott T | buy | 177,936 | $1.41 | [4 2026-05-27] |
| 2026-05-22 | Byam Rebecca | buy | 14,235 | $1.41 | [4 2026-05-27] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | S-1 | Registration statement |
| 2026-10-01 | DEF 14A | Proxy statement |
| 2026-09-24 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-09-10 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-08 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-09-08 | PRE 14A | Proxy statement |
| 2026-08-28 | S-1/A | Registration statement |
| 2026-08-20 | S-1 | Registration statement |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-14 | 10-Q/A | Amended report |
| 2026-08-14 | 8-K | Non-reliance on prior financials |
Alerts for $HCWB
Email me when HCW Biologics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.